Navigation Links
Insmed CEO to Present at Drug Discovery & Development Conference
Date:7/25/2008

CEO Geoffrey Allan Will Discuss Company's IPLEX(TM) Program in Myotonic

Muscular Dystrophy

RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics on Thursday, August 7th, 2008 at 9:25 AM ET.

Dr. Allan will be participating in the Orphan Diseases track of the conference and his presentation will be entitled, "Myotonic Muscular Dystrophy - A Major Unmet Medical Need." He will present Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, which has seen strong patient and physician interest, is now fully enrolled. It is a six month, randomized, double-blind, placebo-controlled trial being conducted at 13 research centers across the U.S.

The conference will be held from August 4th to August 7th, 2008, at the World Trade Center Boston and the Seaport Hotel in Boston, MA.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed to Host Second Quarter 2008 Conference Call
2. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
3. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
4. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
5. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
6. Insmed Announces First Quarter 2008 Financial Results
7. Insmed to Present at CBI Follow-On Biologics Conference
8. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... upscale Capitol Hill neighborhood, with its swanky shops, parks and cafés, ... treatment salon to set up shop. But there,s Hair ... bistro on E Madison Ave, and CEO Maria Botham ... clinic, we pride ourselves on being a destination for parents ... stigma associated with lice. Everyone can get lice – it ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, ... begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. ... healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed on ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):